vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and loanDepot, Inc. (LDI). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 20.5%). Over the past eight quarters, loanDepot, Inc.'s revenue compounded faster (18.0% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
ESPR vs LDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $310.3M |
| Net Profit | — | $-22.5M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | -10.3% |
| Net Margin | — | -7.2% |
| Revenue YoY | 143.7% | 20.5% |
| Net Profit YoY | — | 32.4% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $310.3M | ||
| Q3 25 | $87.3M | $323.3M | ||
| Q2 25 | $82.4M | $282.5M | ||
| Q1 25 | $65.0M | $273.6M | ||
| Q4 24 | $69.1M | $257.5M | ||
| Q3 24 | $51.6M | $314.6M | ||
| Q2 24 | $73.8M | $265.4M | ||
| Q1 24 | $137.7M | $222.8M |
| Q4 25 | — | $-22.5M | ||
| Q3 25 | $-31.3M | $-4.9M | ||
| Q2 25 | $-12.7M | $-13.4M | ||
| Q1 25 | $-40.5M | $-21.9M | ||
| Q4 24 | — | $-33.2M | ||
| Q3 24 | $-29.5M | $1.4M | ||
| Q2 24 | $-61.9M | $-32.2M | ||
| Q1 24 | $61.0M | $-34.3M |
| Q4 25 | 50.6% | -10.3% | ||
| Q3 25 | -11.4% | -3.2% | ||
| Q2 25 | 8.6% | -11.4% | ||
| Q1 25 | -34.0% | -16.8% | ||
| Q4 24 | -6.4% | -32.7% | ||
| Q3 24 | -31.0% | 1.1% | ||
| Q2 24 | 3.5% | -29.1% | ||
| Q1 24 | 52.5% | -38.2% |
| Q4 25 | — | -7.2% | ||
| Q3 25 | -35.9% | -1.5% | ||
| Q2 25 | -15.4% | -4.7% | ||
| Q1 25 | -62.2% | -8.0% | ||
| Q4 24 | — | -12.9% | ||
| Q3 24 | -57.2% | 0.4% | ||
| Q2 24 | -83.9% | -12.1% | ||
| Q1 24 | 44.3% | -15.4% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | $0.01 | ||
| Q2 24 | $-0.33 | $-0.18 | ||
| Q1 24 | $0.34 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $337.2M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $-302.0M | $386.0M |
| Total Assets | $465.9M | $6.9B |
| Debt / EquityLower = less leverage | — | 5.44× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $337.2M | ||
| Q3 25 | $92.4M | $459.2M | ||
| Q2 25 | $86.1M | $408.6M | ||
| Q1 25 | $114.6M | $371.5M | ||
| Q4 24 | $144.8M | $421.6M | ||
| Q3 24 | $144.7M | $483.0M | ||
| Q2 24 | $189.3M | $533.2M | ||
| Q1 24 | $226.6M | $603.7M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $2.0B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.3B |
| Q4 25 | $-302.0M | $386.0M | ||
| Q3 25 | $-451.4M | $433.3M | ||
| Q2 25 | $-433.5M | $439.1M | ||
| Q1 25 | $-426.2M | $469.3M | ||
| Q4 24 | $-388.7M | $506.6M | ||
| Q3 24 | $-370.2M | $592.0M | ||
| Q2 24 | $-344.2M | $578.9M | ||
| Q1 24 | $-294.3M | $637.3M |
| Q4 25 | $465.9M | $6.9B | ||
| Q3 25 | $364.0M | $6.2B | ||
| Q2 25 | $347.1M | $6.2B | ||
| Q1 25 | $324.0M | $6.4B | ||
| Q4 24 | $343.8M | $6.3B | ||
| Q3 24 | $314.1M | $6.4B | ||
| Q2 24 | $352.3M | $5.9B | ||
| Q1 24 | $373.1M | $6.2B |
| Q4 25 | — | 5.44× | ||
| Q3 25 | — | 4.83× | ||
| Q2 25 | — | 4.70× | ||
| Q1 25 | — | 4.30× | ||
| Q4 24 | — | 4.00× | ||
| Q3 24 | — | 3.31× | ||
| Q2 24 | — | 3.41× | ||
| Q1 24 | — | 3.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-638.7M |
| Free Cash FlowOCF − Capex | — | $-648.0M |
| FCF MarginFCF / Revenue | — | -208.9% |
| Capex IntensityCapex / Revenue | 0.0% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-734.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-638.7M | ||
| Q3 25 | $-4.3M | $43.4M | ||
| Q2 25 | $-31.4M | $67.6M | ||
| Q1 25 | $-22.6M | $-179.9M | ||
| Q4 24 | $-35.0M | $47.7M | ||
| Q3 24 | $-35.3M | $-349.2M | ||
| Q2 24 | $-7.2M | $-278.3M | ||
| Q1 24 | $53.8M | $-278.5M |
| Q4 25 | — | $-648.0M | ||
| Q3 25 | — | $38.7M | ||
| Q2 25 | — | $61.4M | ||
| Q1 25 | — | $-186.7M | ||
| Q4 24 | — | $40.8M | ||
| Q3 24 | $-35.5M | $-356.4M | ||
| Q2 24 | $-7.3M | $-285.7M | ||
| Q1 24 | $53.8M | $-283.3M |
| Q4 25 | — | -208.9% | ||
| Q3 25 | — | 12.0% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | -68.2% | ||
| Q4 24 | — | 15.8% | ||
| Q3 24 | -68.7% | -113.3% | ||
| Q2 24 | -9.9% | -107.7% | ||
| Q1 24 | 39.0% | -127.2% |
| Q4 25 | 0.0% | 3.0% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 2.2% | ||
| Q1 25 | 0.0% | 2.5% | ||
| Q4 24 | 0.0% | 2.7% | ||
| Q3 24 | 0.3% | 2.3% | ||
| Q2 24 | 0.1% | 2.8% | ||
| Q1 24 | 0.1% | 2.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -255.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LDI
Segment breakdown not available.
